Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time accessread more...
Benzinga
More News
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
Key Points4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share...
Nasdaq News: Markets
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PR Newswire BERKELEY, Calif., June 9, 2026 BERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell...
PR Newswire
Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA
Jennison Associates LLC boosted its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 262.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,483 shares of the company's stock after purchasing an additional...
MarketBeat
Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday
Palvella Therapeutics (NASDAQ:PVLA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-palvella-therapeutics-stock...
MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the stock, Marketbeat reports...
MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - What's Next?
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - Time to Buy...
MarketBeat
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA
Deltec Asset Management LLC decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent filing with the...
MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Palvella Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat.com...
MarketBeat

Advertisement|Remove ads.